anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a method for treating gouty arthritis by combining oral administration and external application of traditional Chinese medicines. As for oral administration of traditional Chinese medicines: the basic formula of Simiaosan (powder containing four elements) and Wushengtang (a decoction containing five elements) consists of 10g of rhizoma atractylodis, 10g of cortex phellodendri, 10g of medicinal cyathula root, 6g of pseudobulbus cremastrae seu pleiones, 15g of poria cocos, 15g of semen plantaginis, 15g of herba violae, 15g of dioscoreae hypoglaucae root, 30g of honeysuckle flower, 30g of rhizoma smilacis glabrae and 30g of raw coix seed. Ways of adding and subtracting: for local dull skin, the formula is added with 10g of bombyx batryticatus, 10g of lumbricus, 10g of peach kernel and 10g of flos carthami; and for symptom accompanied with red and hot urine, the formula is added with 15g of lysimachia christinae hance. The medicine is taken by one dosage every day, and the medicine is decocted in water and taken for three times. The turn of two weeks is taken as a treatment course. As for external application of traditional Chinese medicines: the formula consists of 10g of radix et rhizoma rhei, 10g of radix scutellariae, 10g of radix coptis and 10g of cortex phellodendri, the medicines are crushed into powder, the crushed medicines are blended with a proper amount of Vaseline so as to obtain a paste, the obtained paste is externally applied to local affected parts and the medicine is changed once every other day. The turn of two weeks is taken as a treatment course. Diet fit and avoided: all patients, as being diagnosed, are advised to take low-purine and low-fat diet. Most traditional Chinese medicines, upon single-medicine pharmacological inspection, are stable and easily available in raw material source, convenient to take, low in cost, free from negative ecological effect and environmental pollution in a production process and good in ecological benefits and prospect. And the traditional Chinese medicines, as natural traditional Chinese medicines, are good in curative effect, free from toxic and side effects, low in cost and convenient to take.
Ceralasertib monotherapy will be administered on a number of days during Cycle 0 to assess the effect of food on ceralasertib absorption and effect of ceralasertib on ECG parameters under various conditions (fasted, fed, steady state). From C1 onwards, patients who participated in C0 will be allocated to either ceralasertib in combination with olaparib or durvalumab, or ceralasertib monotherapy and assessed for safety.
The present invention relates to a prognostic method of pancreatic cancer. In this study, the inventors evaluated the effect of hypoxia and metabolic stress on the regulation of BTN3A isoforms using notably qRT PCR and Western Blotting and found an unexpected soluble form. More, they demonstrated a key role of BTN3 A in Vγ9Vδ2 T cells cytolytic functions against PDAC that are conserved under hypoxia. Finally, they found that BTN3A expression in tissues and plasma level of soluble BTN3 A and BTN3 A1 are associated with poor prognosis in patients with PDAC. Thus, the invention relates to a method for predicting the survival time of a patient suffering from a pancreatic cancer comprising based on the measurement of the expression level of BTN3 A or sBTN3A. More, the invention relates to an anti-CD277 antibody, which activates the cytolytic function, cytokine production and proliferation of T cells for use in the treatment of pancreatic cancer in a patient with a bad prognosis.
The UNC Center for Functional GI \& Motility Disorders Clinic frequently receives referrals for patients with chronic and treatment refractory symptoms of abdominal pain and bowel dysfunction. Many of these patients are diagnosed with irritable bowel syndrome, painful functional constipation or functional abdominal pain syndrome using Rome III criteria. The presenting symptoms of the referral population are frequently in the severe range, with patients having intensely painful symptoms, Axis I and Axis II co-morbidities, and impaired health related quality of life. Failure of multiple standard treatment attempts prior to referral is customary for patients seen in our clinic. Additionally, a greater number of patients only experience a partial response to standard treatment. We are therefore attempting to address these patients utilizing novel treatment strategies such as we propose here.
BACKGROUND AND OBJECTIVE: Lung function reaches a peak/plateau in early adulthood before declining with age. Lower early adult lung function may increase the risk for chronic obstructive pulmonary disease (COPD) in mid-late adult life. Understanding the effects of multiple childhood/adolescent exposures and their potential interactions on plateau lung function would provide insights into the natural history of COPD.
METHODS: Longitudinal spirometry data from 688 participants with complete data from a population-based birth cohort (original n = 1037) were used to investigate associations between a wide range of childhood/adolescent exposures and repeated measures of FEV1, FVC and FEV1/FVC during the early-adult plateau phase. Generalized estimating equations were used to accommodate the multiple timepoints per participant.
RESULTS: FEV1 reached a peak/plateau between ages 18 and 26 and FVC from 21 to 32 years, whereas FEV1/FVC declined throughout early adulthood. Childhood asthma and airway hyperresponsiveness were associated with lower early adult FEV1 and FEV1/FVC. Smoking by age 18 was associated with lower FEV1/FVC. Higher BMI during early adulthood was associated with lower FEV1 and FVC and lower FEV1/FVC. Physical activity during adolescence was positively associated with FEV1 and FEV1/FVC but this was only statistically significant in men. There was no convincing evidence of interactions between exposures.
CONCLUSION: Childhood asthma and airway hyperresponsiveness are associated with lower lung function in early adulthood. Interventions targeting these may reduce the risk of COPD in mid-late adult life. Promotion of physical activity during adolescence, prevention of cigarette smoking and maintenance of a healthy body weight in early adulthood are also priorities.
Obesity is associated with a wide range of complications, including type 2 diabetes mellitus, cardiovascular disease, hypertension and nonalcoholic fatty liver disease. Obesity also increases the incidence and progression of cancers, autoimmunity and infections, as well as lowering vaccine responsiveness. A unifying concept across these differing diseases is dysregulated immunity, particularly inflammation, in response to metabolic overload. Herein, we review emerging mechanisms by which obesity drives inflammation and autoimmunity, as well as impairing tumour immunosurveillance and the response to infections. Among these mechanisms are obesity-associated changes in the hormones that regulate immune cell metabolism and function and drive inflammation. The cargo of extracellular vesicles derived from adipose tissue, which controls cytokine secretion from immune cells, is also dysregulated in obesity, in addition to impairments in fatty acid metabolism related to inflammation. Furthermore, an imbalance exists in obesity in the biosynthesis and levels of polyunsaturated fatty acid-derived oxylipins, which control a range of outcomes related to inflammation, such as immune cell chemotaxis and cytokine production. Finally, there is a need to investigate how obesity influences immunity using innovative model systems that account for the heterogeneous nature of obesity in the human population.
Subjects will apply VYN201 vehicle (placebo) once daily on affected vitiligo areas. The first part of the study will be a 24-week, double-blind, vehicle controlled treatment period. Following, the second part will be a 28-week, double-blind treatment extension period, with a 4-week safety follow-up period after the last investigational medicinal product (IMP) dose. After completion of the Week 24 assessments, subjects randomized to vehicle (placebo) will be re-randomized to 1 of the 3 higher VYN201 (active) dose groups (1.0%, 2.0% or 3.0% once daily) in a 1:1:1 ratio while maintaining the blind until Week 52.
Percutaneous procedure will be performed under standard conditions, under transabdominal ultrasound guidance. After choosing the optimum needle trajectory, the skin site will be marked, standard skin sterilization with iodine and surgical draping of the site will be performed. Local anesthesia of the site with gradual lidocaine solution infiltration of the skin and underlying planes will be performed. Under ultrasound guidance, with collaboration of the patient for the respiratory movements, one or two passages with a 16G needle will be performed (BARD Max Core 16G, Becton Dickinson, USA). Specimens will be collected in formalin and send to pathology for processing.
We aimed to map the topics and trends of research on digital health for myocardial infarction over the past ten years. This can inform future research directions and newly emerging topics for myocardial infarction care, diagnosis and monitoring. The Web of Science database was searched for papers related to digital health for myocardial infarction. 1,344 retrieved records were used for visualisation through bibliometrics and co-occurrence network analysis of keywords. Our mapping revealed several emerging topics in recent years, including artificial intelligence and deep learning. Higher emphasis on automated and artificially intelligent digital health systems in recent years can inform future clinical practice and research directions for myocardial infarction.
As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.

Bulging fontanels in infants and benign intracranial hypertension in adults have been reported in individuals receiving tetracyclines. These conditions disappeared when the drug was discontinued.

Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy when indicated.

Prescribing Doxycycline Monohydrate Capsules in the absence of proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
PURPOSE:To obtain an antimutagen, having excellent antimutagenicity and capable of detoxicating carcinogens present in living environment by assimilating silicon in a culture solution of a mold. CONSTITUTION:A silicon compound (e.g. beta-carboxyethylsilicon sesquioxide) is added to a culture solution of a mold and cultured to assimilate silicon. Thereby, an antimutagen composed of a silicon conjugated protein, silicon conjugated polysaccharide protein, etc., is obtained. A mold of the genus Aspergillus or Basidiomycetes is suitable as the mold and KOJI mold, black KOKI mold, fungi of Lentinus edodes Sing., Flammulina velutipes Sing., etc., are cited as specific examples thereof. If the resultant antimutagen is always ingested, carcinogens present in living environment can be detoxicated. Thereby, the carcinogenic rate can be lowered.
A hemostatic agent, method and carrier for arresting the flow of blood and other protein containing body fluids flowing from an open wound and for promoting wound healing. A broad aspect is directed to a substantially anhydrous admixture of an oxyacid salt and a hydrophilic proton donor which will hydrate in the presence of blood and body fluid to produce cations to promote blood clotting. The preferred oxyacid salts are alkali and alkaline earth salts of transition metals and halogen oxyacids with oxidizing capabilities sufficient to accelerate blood clotting. Another embodiment of the invention includes the compound containing an oxysalt plus a hydrophilic polymer such as carboxy methylcellulose, polyvinyl, alcohol, an alginate, and all soluble gums. Still another embodiment of the invention includes the compound formed of an oxyacid salt in combination with a hydrophilic proton donor and a solid desiccant which further accelerates blood coagulation reaction rates. The cation exchange material or an admixture of an alkali metal oxyacid salt plus acidic inorganic salt produces a scab or protective coating over the wound for protection and enhanced healing. Oxygen produced during the reaction substantially reduces the level of bacteria, virus and fungus at the wound. The resin is performance-enhanced for greater fluid uptake and more rapid coagulation.
Apparatus and associated methods relate to inducing ectodermal stimulation by substantially continuous topical application of a therapeutic dose of vascular growth induction agent (VGIA) and moisturizing compound. The moisturizing compound may, for example promote skin health and/or penetration of the VGIA to target cells. The VGIA may, for example, promote vascularization, neurostimulation, and/or oxygenation. In an illustrative example, the VGIA may, for example, include minoxidil. The moisturizing compound may, for example, include lactic acid. In some implementations, the VGIA and moisturizing compound may be substantially continuously topically applied by a cream. In some implementations, the VGIA and moisturizing compound may be substantially continuously topically applied by a controlled-release application device. Various embodiments may advantageously induce reversal of disease processes at the ectodermal level in affected peripheral body portions (e.g., feet, legs, hands).
A pellet delivery system is provided that comprises a needle having an inner surface defining a passageway. The needle has a first portion that extends along a longitudinal axis and a curved second portion comprising an opening that is in communication with the passageway. The second portion extends transverse to the longitudinal axis. A pellet is positioned in the passageway. A plunger is slidably positioned in the passageway. The plunger comprises a shaft having a rounded tip configured to push the pellet through the first and second portions and out of the opening without the pellet becoming stuck within the passageway or the opening. Implants, systems, constructs, instruments and methods are disclosed.
INTRODUCTION AND HYPOTHESIS: The aim of this study is to compare the effectiveness of transcutaneous tibial nerve stimulation (TTNS) on quality of life (QoL) and clinical parameters related to incontinence in pharmacological agents (PhAs) naive and refractory women with idiopathic overactive bladder (iOAB).
METHODS: In this prospective nonrandomized clinical trial, women with resistance to PhAs were included in the first group (n=21), PhA-naive women were included in the second group (n=21). TTNS was performed 2 days a week, a total of 12 sessions for 6 weeks. Every session lasted 30 min. Women were evaluated for the severity of incontinence (Pad test), 3-day voiding diary (voiding frequency, nocturia, incontinence episodes, and number of pads), symptom severity (Overactive Bladder Questionnaire-V8), quality of life (Incontinence Impact Questionnaire-7), treatment satisfaction, positive response, and cure-improvement rates.
RESULTS: A statistically significant improvement was found in all parameters for each group at the 6th week compared with the baseline values (p<0.05). It was found that the severity of incontinence, incontinence episodes, symptom severity, treatment satisfaction, and QoL parameters were significantly improved in PhA-naive group compared with the PhA-resistant group at the 6th week (p<0.05). There were no statistically significant differences in the frequency of voiding, nocturia, and number of pads between the two groups (p>0.05). Positive response rates, the primary outcome measure, were statistically significantly higher in the PhA-naive group than in the PhA-resistant group.
CONCLUSIONS: Although TTNS is more effective in PhA-naive women with iOAB, it appears to be an effective therapy that can also be used in the management of PhA-resistant women with iOAB.
Diabetic wound healing is a significant clinical challenge because abnormal immune cells in the wound cause chronic inflammation and impair tissue regeneration. Therefore, regulating the behavior and function of macrophages may be conducive to improving treatment outcomes in diabetic wounds. Herein, sulfated chitosan (26SCS)-containing composite sponges (26SCS-SilMA/Col-330) with well-arranged layers and high porosity were constructed based on collagen and silk fibroin, aiming to induce an appropriate inflammatory response and promote angiogenesis. The results indicated that the ordered topological structure of composite sponges could trigger the pro-inflammatory response of Mφs in the early stage, and rapid release of 26SCS in the early and middle stages (within the concentration range of 1-3 mg/mL) induced a positive inflammatory response; initiated the pro-inflammatory reaction of Mφs within 3 days; shifted M1 Mφs to the M2 phenotype within 3-7 days; and significantly up-regulated the expression of two typical angiogenic growth factors, namely VEGF and PDGF-BB, on day 7, leading to rapid HUVEC migration and angiogenesis. In vivo data also demonstrated that on the 14th day after surgery, the 26SCS-SilMA/Col-330-implanted areas exhibited less inflammation, faster re-epithelialization, more abundant collagen deposition and a greater number of blood vessels in the skin tissue. The composite sponges with higher 26SCS contents (the (5.0) 26SCS-SilMA/Col-330 and the (7.5) 26SCS-SilMA/Col-330) could better orchestrate the phenotype and function of Mφs and facilitate wound healing. These findings highlight that the 26SCS-SilMA/Col-330 sponges developed in this work might have great potential as a novel dressing for the treatment of diabetic wounds.
IV midazolam will be administered for sedation while patient is mechanically ventilated. Patient will be monitored per standard of care in the CICU using the Richmond Agitation and Sedation Scale (RASS) with a set goal sedation level of RASS 0 to -2. Pain will be monitored based on the Critical-Care Pain Observation Tool (CPOT) assessment with goal less than or equal to 2. Delirium will be evaluated based on the Confusion Assessment Method for the ICU (CAM-ICU) with goal of negative or patient's baseline.
Kyphotic deformity following the loss of cervical lordosis can lead to unfavourable neurological recovery after cervical laminoplasty (CLP); therefore, it is essential to identify its risk factors. Recent studies have demonstrated that the dynamic parameters of the cervical spine, based on baseline flexion/extension radiographs, are highly useful to estimate the loss of cervical lordosis after CLP. However, it remains unclear whether such dynamic parameters can predict kyphotic deformity development after CLP. Hence, the present study aimed to investigate whether the dynamic parameters could predict kyphotic deformity in patients with cervical spondylotic myelopathy (CSM) after CLP. This retrospective study included 165 patients, consisting of 10 and 155 patients with and without cervical kyphosis of C2-C7 angle ≤ -10° at the final follow-up period, respectively. Among the static and dynamic parameters of the cervical spine, greater cervical kyphosis during flexion (fC2-C7 angle) demonstrated the best discrimination between these two cohorts, with an optimal cutoff value of -27.5°. Meanwhile, greater gap range of motion (gROM = flexion ROM - extension ROM ) had the highest ability to predict a loss of ≥ 10° in C2-C7 angle after CLP, with an optimal cutoff value of 28.5°. This study suggests that in patients with CSM, fC2-C7 angle ≤ -25° on baseline radiographs is a potential risk for kyphotic deformity after CLP. In clinical practice, the patients with this criterion (fC2-C7 angle ≤ -25°) along with gROM ≥ 30° are at high risk of developing significant kyphotic deformity after CLP.
PURPOSE: An external use skin composition is provided to have a safe skin whitening effect without skin irritation using tengeretin contained in a citrus peel extract and epigallocatechin gallate (EGCG) contained in a green tea extract. CONSTITUTION: An external use skin composition contains tangeretin and EGCG. Tangeretin is contained in a citrus peel extract. EGCG is contained in a green tea extract. The composition contains 0.001-10 wt% of a citrus peel extract and 0.001-99.9 wt% of the green tea extract. [Reference numerals] (AA) p-value of each value treated with tangeretin < 0.05
FIELD: medicine. ^ SUBSTANCE: group of inventions relates to field of veterinary medicine. Combined vaccine against dog's leptospirosis contains preparation of Leptospira cells from Leptospira bratislava, Leptospira canicola, Leptospira grippotyphosa, Leptospira icterohaemorrhagiae and Leptospira pomona and a carrier. Quantity of each Leptospira strain in combined vaccine is in the range of nearly 100-3500 nephelometric units per a dose of vaccine. Combined vaccine for immunisation of dogs against dogs' pathogens additionally contains attenuated strain Snyder Hill of dogs plague virus (CD), attenuated strain Manhattan of adenovirus of dogs of 2 type (CAV-2), attenuated strain of virus NL-CPI-5 of dogs parainfluenza (CPI), attenuated strain NL-35-D of dogs' parvovirus (CPV) and carrier, where said virus CD, CAV-2, virus CPI and CPV are in the range from ot 102 to 109 TCID50 (inflectional dose with 50% cytopathic effect in tissue culture) per a dose. Method of dog's protection against leptospirosis and other pathogens includes introduction to a dog of said above combined vaccines in therapeutically effective quantity. ^ EFFECT: vaccines and method have high efficiency, are harmless. ^ 15 cl, 4 dwg, 49 tbl, 6 ex
The present invention is with oyster shuck powder as carrier to prepare potassium chloride stomach retention floating type slow release tablet, belonging to pharmaceutical preparation technique field. The technique is characterized in that its main components are oyster shuck powder and potassium chloride. The tablet can retain in stomach and prolong the medicine releasing time, improve the medicine absorption, be beneficial to promote bioavialability. The preparing technique process of the present invention is simple, convenient and reasonable operation, suitable for industrial production. And the price is achievement, using convenient, beneficial to large scale spreading and application. The medicine has calcium-replenishing function while treating hypokalemia, and relieved toxic effect of potassium ion to heart. The present invention has little dosage, good effect, and good market prospect.
The experimental group will receive Bowen therapy according to ISBT Bowen Therapy® (Black \& Murray, 2005). It may include sequences 1, 4, 2, hamstrings (movements 1-6) and sacrum sequences in the prone position, and hamstrings sequence (7-18 movements) and 3 in the supine position,. The sequences may also include Bowen movements in the scalenes, trapezius, all erector spinae, sacro-iliac joint ligaments, gluteus maximus and medius, tensor fasciae latae, and gastrocnemius. The application of Bowen sequences is varied between sessions and participants depending on the presenting functional deficit and treatment response.
The twin pairs discordant for incident obesity (iOB) \[11 monozygotic (MZ) and 15 dizygotic twin pairs (DZ)\] are included from the National Heart, Lung, and Blood Institute (NHLBI) Twin Study (NTS). In a discordant twin pair, one co-twin developed iOB while his co-twin did not or develop iOB at least one year later.
Three volunteers will receive 3 ascending doses of PfSPZ Vaccine by IV administration four weeks apart. The three doses are 3x10\^4, 1.35x10\^5, and 2.7x10\^5 PfSPZ. This is the safety group that will be inoculated first before all others for demonstration of safety and will be followed up for assessment of safety after the completion of the three doses. The follow up will be at weeks 1, 2, 4, 8 and 24 after completion of vaccination. Volunteers in Group 1 will not undergo CHMI. Group 1 is unblinded.